A Phase 4 interventional study of Olaparib in Ovarian Cancer and Breast Cancer, sponsored by AstraZeneca. Completed at 16 sites in India. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 18th largest by enrollment, is one of 6 that started in 2020, is one of 3 in phase 4, and was the 44th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 99 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 97 across the 69 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 21st largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2020, is one of 2 in phase 4, and was the 46th registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA (BReast CAncer gene) 1/2 Mutation
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA(BReast CAncer gene)1/2 Mutation As per recommendation from DCGI(Drug Controller general of of India), the current phase-IV study is planned with the aim to assess the safety in Indian subjects receiving olaparib as per the approved label indications in India in accordance with the requirements of the Health Authorities of India. This study attempts to descriptively elucidate the safety of Olaparib in Indian subjects receiving olaparib as per the Indian regulatory approved indications in India. The data obtained from the present study will help to understand the safety profile of olaparib in Indian patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects receiving olaparib for the following indications in ovarian cancer:
for the maintenance treatment of adult subjects with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy
in subjects with deleterious or suspected deleterious gBRCAm, -negative breast cancer who have previously been treated with chemotherapy in the , adjuvant or metastatic setting. Subjects with HR-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Drug: Olaparib
Drug: Olaparib
Tablet
Haematology: Basophils Absolute Count, Eosinophils Absolute Count, Leucocytes WBC, Lymphocytes Absolute Count, Monocytes Absolute Count, Neutrophils Absolute Count, and Platelets Parameters
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Comparison between the cohorts was not the objective for the study. The hematology data were analyzed as above normal/normal/below normal and are presented as end of treatment status for the overall population . EOT = end of treatment
Time frame: Baseline to EOT (approximately 6 months)
Haematology: Haemoglobin Parameters
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. The haemoglobin parameter data were analyzed as above normal/normal/below normal and are presented as end of treatment status for the overall population . EOT = end of treatment
Time frame: Baseline to EOT (approximately 6 months)
Number of Participants Who Experienced a Shift in Hematology Parameters to Results Classified as Below Normal at EOT
The number of participants who experienced hematology results classified as normal at Baseline which shifted to below normal at the End of Treatment visit are presented. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. EOT = end of treatment
Time frame: Baseline to EOT (approximately 6 months)
Number of Participants Who Experienced a Shift in Hemoglobin Parameters to Results Classified as Below Normal at EOT
The number of participants who experienced hemoglobin results classified as normal at Baseline which shifted to below normal at the End of Treatment visit are presented.. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. EOT = end of treatment
Time frame: Baseline to EOT (approximately 6 months)
Number of Participants With Remarkable Changes in Clinical Chemistry Values Over Time as Assessed by Investigator
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Remarkable changes were assessed by the investigator. EOT = end of treatment
Time frame: Baseline to EOT (approximately 6 months)
Number of Participants With Remarkable Changes in Physical Examination Over Time as Assessed by Investigator
Abnormal clinically significant results at Baseline and EOT are presented. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib.
Time frame: Baseline to EOT (approximately 6 months)
Number of Participants With Remarkable Changes in Vital Signs Over Time as Assessed by Investigator
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Remarkable changes were assessed by the investigator. EOT = end of treatment
Time frame: Baseline to EOT (approximately 6 months)
WHO Performance Status
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib.
Time frame: Baseline and End of study visit (200 days)
Participants who were prescribed olaparib by an independent clinical judgement of investigator in his/her routine practice based on locally approved prescribing information were eligible for screening under this study.
| Milestone | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer |
|---|---|---|---|
| Started | 163 | 38 | 1 |
| Completed | 104 | 18 | 1 |
| Not completed | 59 | 20 | 0 |
| Withdrew: Other: adverse event | 5 | 0 | 0 |
| Withdrew: Disease progression | 38 | 10 | 0 |
| Withdrew: Physician decision | 5 | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Death | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 0 |
| Withdrew: Other: increased qtc interval and clinical progression found | 0 | 1 | 0 |
| Withdrew: Other: progressive disease (no confirming documents) | 0 | 1 | 0 |
| Withdrew: Other: disease progression | 1 | 0 | 0 |
| Withdrew: Other: due to anemia the investigator decided not to continue | 1 | 0 | 0 |
| Withdrew: Other: due to disease progression and could not tolerate the dose | 1 | 0 | 0 |
| Withdrew: Enrolled and did not receive study drug (not included in safety analysis set) | 2 | 0 | 0 |
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Comparison between the cohorts was not the objective for the study. The hematology data were analyzed as above normal/normal/below normal and are presented as end of treatment status for the overall population . EOT = end of treatment
| Participants | Ovarian | Breast Cancer | Both Ovarian and Breast Cancer | Cancer Type: Overall |
|---|---|---|---|---|
| Basophils Absolute Count — EOT Above Normal | 0 | 0 | 0 | 0 |
| Basophils Absolute Count — EOT Normal | 72 | 12 | 1 | 85 |
| Basophils Absolute Count — EOT Below Normal | 41 | 10 | 0 | 51 |
| Basophils Absolute Count — EOT Missing | 48 | 16 | 0 | 64 |
| Eosinophils Absolute Count — EOT Above Normal | 2 | 0 | 0 | 2 |
| Eosinophils Absolute Count — EOT Normal | 90 | 20 | 1 | 111 |
| Eosinophils Absolute Count — EOT Below Normal | 21 | 3 | 0 | 24 |
| Eosinophils Absolute Count — EOT Missing | 48 | 15 | 0 | 63 |
| Leucocytes WBC — EOT Above Normal | 2 | 1 | 0 | 3 |
| Leucocytes WBC — EOT Normal | 101 | 17 | 1 | 119 |
| Leucocytes WBC — EOT Below Normal | 27 | 8 | 0 | 35 |
| Leucocytes WBC — EOT Missing | 31 | 12 | 0 | 43 |
| Lymphocytes Absolute Count — EOT Above Normal | 0 | 0 | 0 | 0 |
| Lymphocytes Absolute Count — EOT Normal | 79 | 10 | 0 | 89 |
| Lymphocytes Absolute Count — EOT Below Normal | 51 | 16 | 1 | 68 |
| Lymphocytes Absolute Count — EOT Missing | 31 | 12 | 0 | 43 |
| Monocytes Absolute Count — EOT Above Normal | 3 | 1 | 0 | 4 |
| Monocytes Absolute Count — EOT Normal | 84 | 14 | 1 | 99 |
| Monocytes Absolute Count — EOT Below Normal | 26 | 8 | 0 | 34 |
| Monocytes Absolute Count — EOT Missing | 48 | 15 | 0 | 63 |
| Neutrophils Absolute Count — EOT Above Normal | 2 | 1 | 0 | 3 |
| Neutrophils Absolute Count — EOT Normal | 107 | 19 | 1 | 127 |
| Neutrophils Absolute Count — EOT Below Normal | 21 | 6 | 0 | 27 |
| Neutrophils Absolute Count — EOT Missing | 31 | 12 | 0 | 43 |
| Platelets — EOT Above Normal | 18 | 6 | 1 | 25 |
| Platelets — EOT Normal | 69 | 13 | 0 | 82 |
| Platelets — EOT Below Normal | 43 | 7 | 0 | 50 |
| Platelets — EOT Missing | 31 | 12 | 0 | 43 |
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. The haemoglobin parameter data were analyzed as above normal/normal/below normal and are presented as end of treatment status for the overall population . EOT = end of treatment
| Participants | Ovarian Cancer | Breast Cancer | Both Ovarian and Breast Cancer | Cancer Type: Overall |
|---|---|---|---|---|
| EOT Above Normal | 0 | 0 | 0 | 0 |
| EOT Normal | 15 | 5 | 0 | 20 |
| EOT Below Normal | 115 | 21 | 1 | 137 |
| EOT Missing | 31 | 12 | 0 | 43 |
The number of participants who experienced hematology results classified as normal at Baseline which shifted to below normal at the End of Treatment visit are presented. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. EOT = end of treatment
| Participants | Ovarian Cancer | Breast Cancer | Both Ovarian and Breast Cancer | Cancer Type: Overall |
|---|---|---|---|---|
| Basophils Absolute Count | 13 | 5 | 0 | 18 |
| Eosinophils Absolute Count | 8 | 2 | 0 | 10 |
| Leucocytes WBC | 17 | 6 | 0 | 23 |
| Lymphocytes Absolute Count | 20 | 8 | 1 | 29 |
| Monocytes Absolute Count | 21 | 6 | 0 | 27 |
| Neutrophils Absolute Count | 9 | 5 | 0 | 14 |
| Platelets | 23 | 4 | 0 | 27 |
The number of participants who experienced hemoglobin results classified as normal at Baseline which shifted to below normal at the End of Treatment visit are presented.. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. EOT = end of treatment
| Participants | Ovarian Cancer | Breast Cancer | Both Ovarian and Breast Cancer | Cancer Type: Overall |
|---|---|---|---|---|
| Number of Participants Who Experienced a Shift in Hemoglobin Parameters to Results Classified as Below Normal at EOT | 17 | 11 | 0 | 28 |
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Remarkable changes were assessed by the investigator. EOT = end of treatment
| Participants | Ovarian Cancer | Breast Cancer | Both Ovarian and Breast Cancer |
|---|---|---|---|
| Number of Participants With Remarkable Changes in Clinical Chemistry Values Over Time as Assessed by Investigator | 0 | 0 | 0 |
Abnormal clinically significant results at Baseline and EOT are presented. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib.
| Participants | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer |
|---|---|---|---|
| Abnormal Clinically Significant result at Baseline — Physical Examination Status | 0 | 0 | 0 |
| Abnormal Clinically Significant result at Baseline — General Appearance | 0 | 0 | 0 |
| Abnormal Clinically Significant result at Baseline — Respiratory | 0 | 0 | 0 |
| Abnormal Clinically Significant result at Baseline — Cardiovascular | 0 | 0 | 0 |
| Abnormal Clinically Significant result at Baseline — Abdomen | 0 | 0 | 0 |
| Abnormal Clinically Significant result at Baseline — Lymph Nodes | 0 | 0 | 0 |
| Abnormal Clinically Significant result at Baseline — Musculoskeletal system | 0 | 1 | 0 |
| Abnormal Clinically Significant result at Baseline — No response | 161 | 37 | 1 |
| Abnormal Clinically Significant result at End of Treatment — Physical Examination Status | 2 | 1 | 0 |
| Abnormal Clinically Significant result at End of Treatment — General Appearance | 0 | 0 | 0 |
| Abnormal Clinically Significant result at End of Treatment — Respiratory | 1 | 1 | 0 |
| Abnormal Clinically Significant result at End of Treatment — Cardiovascular | 0 | 0 | 0 |
| Abnormal Clinically Significant result at End of Treatment — Abdomen | 1 | 0 | 0 |
| Abnormal Clinically Significant result at End of Treatment — Lymph Nodes | 0 | 1 | 0 |
| Abnormal Clinically Significant result at End of Treatment — Musculoskeletal system | 0 | 0 | 0 |
| Abnormal Clinically Significant result at End of Treatment — No response | 157 | 35 | 1 |
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Remarkable changes were assessed by the investigator. EOT = end of treatment
| Participants | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer |
|---|---|---|---|
| Number of Participants With Remarkable Changes in Vital Signs Over Time as Assessed by Investigator | 0 | 0 | 0 |
The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib.
| Participants | Ovarian Cancer | Breast Cancer | Both Ovarian and Breast Cancer | Cancer Type: Overall |
|---|---|---|---|---|
| Baseline — Normal activity | 155 | 38 | 1 | 194 |
| Baseline — Restricted activity | 6 | 0 | 0 | 6 |
| Baseline — In bed less than or equal to 50% of the time | 0 | 0 | 0 | 0 |
| End of Study — Normal activity | 92 | 12 | 0 | 104 |
| End of Study — Restricted activity | 7 | 1 | 0 | 8 |
| End of Study — In bed less than or equal to 50% of the time | 1 | 0 | 0 | 1 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ovarian Cancer | 3/161 (1.9%) | 24/161 (14.9%) | 148/161 (91.9%) |
| Breast Cancer | 3/38 (7.9%) | 7/38 (18.4%) | 30/38 (78.9%) |
| Both Ovarian Cancer and Breast Cancer | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Event | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer |
|---|---|---|---|
| Retinal vascular occlusionEye disorders | 0/161 | 0/38 | 1/1 |
| AnaemiaBlood and lymphatic system disorders | 12/161 | 2/38 | 0/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/161 | 2/38 | 0/1 |
| CoagulopathyBlood and lymphatic system disorders | 0/161 | 1/38 | 0/1 |
| Increased tendency to bruiseBlood and lymphatic system disorders | 0/161 | 1/38 | 0/1 |
| NeutropeniaBlood and lymphatic system disorders | 0/161 | 1/38 | 0/1 |
| Abdominal painGastrointestinal disorders | 3/161 | 1/38 | 0/1 |
| Abdominal distensionGastrointestinal disorders | 0/161 | 1/38 | 0/1 |
| ConstipationGastrointestinal disorders | 0/161 | 1/38 | 0/1 |
| AstheniaGeneral disorders | 1/161 | 1/38 | 0/1 |
| Event | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer |
|---|---|---|---|
| AstheniaGeneral disorders | 13/161 | 3/38 | 1/1 |
| AnaemiaBlood and lymphatic system disorders | 82/161 | 14/38 | 0/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 35/161 | 5/38 | 0/1 |
| NauseaGastrointestinal disorders | 33/161 | 3/38 | 0/1 |
| VomitingGastrointestinal disorders | 27/161 | 4/38 | 0/1 |
| FatigueGeneral disorders | 25/161 | 3/38 | 0/1 |
| Decreased appetiteMetabolism and nutrition disorders | 18/161 | 5/38 | 0/1 |
| LeukopeniaBlood and lymphatic system disorders | 18/161 | 3/38 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 18/161 | 2/38 | 0/1 |
| ConstipationGastrointestinal disorders | 10/161 | 4/38 | 0/1 |
All enrolled participants
| Age, Continuous(years) | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer | Total |
|---|---|---|---|---|
| Mean | 53.2 ± 8.78 | 44.3 ± 11.85 | 57.0 ± NA | 51.5 ± 10.01 |
| Sex: Female, Male(Participants) | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer | Total |
|---|---|---|---|---|
| Female | 163 | 38 | 1 | 202 |
| Male | 0 | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Body mass index(kg/m2) | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer | Total |
|---|---|---|---|---|
| Mean | 26.204 ± 4.5366 | 24.699 ± 4.7282 | 21.210 ± NA | 25.896 ± 4.6000 |
| Child Bearing Potential(Participants) | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer | Total |
|---|---|---|---|---|
| Yes | 1 | 12 | 0 | 13 |
| No | 162 | 26 | 1 | 189 |
| Stage/FIGO Stage of Cancer at Screening(Participants) | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer | Total |
|---|---|---|---|---|
| Stage IA | 4 | 2 | 0 | 6 |
| Stage IB | 0 | 1 | 0 | 1 |
| Stage IC | 5 | 0 | 0 | 5 |
| Stage IIA | 1 | 3 | 0 | 4 |
| Stage IIB | 2 | 1 | 0 | 3 |
| Stage IIIA | 12 | 3 | 0 | 15 |
| Stage IIIB | 6 | 3 | 0 | 9 |
| Stage IIIC | 60 | 9 | 0 | 69 |
| Stage IVA | 42 | 10 | 1 | 53 |
| Stage IVB | 29 | 6 | 0 | 35 |
| Missing | 2 | 0 | 0 | 2 |
| Previous Cancer Therapy(Participants) | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer | Total |
|---|---|---|---|---|
| 1 cancer therapy regimen | 2 | 8 | 0 | 10 |
| 2 cancer therapy regimens | 55 | 10 | 1 | 66 |
| More than 2 cancer therapy regimens | 106 | 19 | 0 | 125 |
| No | 0 | 1 | 0 | 1 |
| WHO Performance Status(Participants) | Ovarian Cancer | Breast Cancer | Both Ovarian Cancer and Breast Cancer | Total |
|---|---|---|---|---|
| Normal activity | 157 | 38 | 1 | 196 |
| Restricted activity | 6 | 0 | 0 | 6 |
| In bed less than or equal to 50% of the time | 0 | 0 | 0 | 0 |
| In bed more than 50% of the time | 0 | 0 | 0 | 0 |
| 100% bedridden | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from May 2020 to primary completion in Sep 2022, 28 months.
Results were first posted in Mar 2025, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib